Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy

Vaccine

Volumn 26, Issue 22, 2008, Pages 2738-2745

  Valor, L ^a   Navarro, J ^a   Carbone, J ^a   Rodriguez Sainz C ^a   Gil, J ^a   Lopez F ^b   Fernandez Cruz E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Nufarm 21   (Spain)

Author keywords

CD4+ and CD8+ HIV 1 specific lymphoproliferative responses; Cytotoxic T lymphocyte (CTL) precursors; HIV 1 immunogen; Therapeutic vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PLACEBO; POL PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; GENE FREQUENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; AIDS VACCINES; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; PLACEBOS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 43049183568     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.019     Document Type: Article

References (37)

1. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 9 (1994) 6103-6110
2. Altfeld M., Addo M.M., Rosenberg E.S., Hecht F.M., Lee P.K., Vogel M., et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids 17 18 (2003) 2581-2591
3. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 7 (1994) 4650-4655
4. Migueles S.A., and Connors M. The role of CD4(+) and CD8(+) T cells in controlling HIV infection. Curr Infect Dis Rep 4 5 (2002) 461-467
5. Draenert R., Verrill C.L., Tang Y., Allen T.M., Wurcel A.G., Boczanowski M., et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol 78 2 (2004) 630-641
6. Arrode G., Finke J.S., Zebroski H., Siegal F.P., and Steinman R.M. CD8+ T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur J Immunol 35 1 (2005) 159-170
7. Sandberg J.K., Fast N.M., and Nixon D.F. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol 167 1 (2001) 181-187
8. Zimmerli S.C., Harari A., Cellerai C., Vallelian F., Bart P.A., and Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 102 20 (2005) 7239-7244
9. Wahren B., and Liu M. Therapeutic vaccination against HIV. Expert Rev Vac 3 4 Suppl. (2004) S179-S188
10. Bourinbaiar A.S., and Abulafia-Lapid R. Clinical experience with therapeutic AIDS vaccines. Expert Rev Vac 4 3 (2005) 289-304
11. Bahr G. Immune deficiency in HIV-1 infection: novel therapeutic approaches targeting innate and adaptive responses. Expert Rev Clin Immunol 1 4 (2005) 529-547
12. Fernandez-Cruz E., Moreno S., Navarro J., Clotet B., Bouza E., Carbone J., et al. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 22 23-24 (2004) 2966-2973
13. Fernandez-Cruz E., Navarro J., Rodriguez-Sainz C., Gil J., Moreno S., Gonzalez-Lahoz J., et al. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection. Expert Rev Vac 2 6 (2003) 739-752
14. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204 6 (2007) 1405-1416
15. Andrieu J.M., and Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J Intern Med 261 2 (2007) 123-131
16. Lichterfeld M., Kaufmann D.E., Yu X.G., Mui S.K., Addo M.M., Johnston M.N., et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 200 6 (2004) 701-712
17. Angulo R., and Fulcher D.A. Measurement of Candida-specific blastogenesis: comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression. Cytometry 34 3 (1998) 143-151
18. Fulcher D., and Wong S. Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory. Immunol Cell Biol 77 6 (1999) 559-564
19. Novak E.J., Liu A.W., Nepom G.T., and Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 104 12 (1999) R63-R67
20. Wells A.D., Gudmundsdottir H., and Turka L.A. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 100 12 (1997) 3173-3183
21. Larsson M., Jin X., Ramratnam B., Ogg G.S., Engelmayer J., Demoitie M.A., et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. Aids 13 7 (1999) 767-777
22. Rodriguez D., Rodriguez J.R., Rodriguez J.F., Trauber D., and Esteban M. Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses. Proc Natl Acad Sci USA 86 4 (1989) 1287-1291
23. Lichterfeld M., Pantaleo G., and Altfeld M. Loss of HIV-1-specific T cell proliferation in chronic HIV-1 infection: cause or consequence of viral replication?. AIDS 19 11 (2005) 1225-1227
24. McNeil A.C., Shupert W.L., Iyasere C.A., Hallahan C.W., Mican J.A., Davey R.T., et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci USA 98 24 (2001) 13878-13883
25. Iyasere C., Tilton J.C., Johnson A.J., Younes S., Yassine-Diab B., Sekaly R.P., et al. Diminished proliferation of human immunodeficiency virus-specific CD4+T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol 77 20 (2003) 10900-10909
26. Spiegel H.M., DeFalcon E., Ogg G.S., Larsson M., Beadle T.J., Tao P., et al. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis 180 2 (1999) 359-368
27. Moss P.A., Rowland-Jones S.L., Frodsham P.M., McAdam S., Giangrande P., McMichael A.J., et al. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci USA 92 13 (1995) 5773-5777
28. Betts M.R., Krowka J.F., Kepler T.B., Davidian M., Christopherson C., Kwok S., et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses 15 13 (1999) 1219-1228
29. Robbins G.K., Addo M.M., Troung H., Rathod A., Habeeb K., Davis B., et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 17 8 (2003) 1121-1126
30. Maino V.C., Suni M.A., Wormsley S.B., Carlo D.J., Wallace M.R., and Moss R.B. Enhancement of HIV type 1 antigen-specific CD4+T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res Hum Retroviruses 16 18 (2000) 2065-2066
31. Moss R.B., Wallace M.R., Steigbigel R.T., Morrison S.A., Giermakowska W.K., Nardo C.J., et al. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination. Clin Exp Immunol 128 2 (2002) 359-364
32. Moss R.B., Webb E., Giermakowska W.K., Jensen F.C., Savary J.R., Wallace M.R., et al. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. J Acquir Immune Defic Syndr 24 3 (2000) 264-269
33. Valentine F.T., Kundu S., Haslett P.A., Katzenstein D., Beckett L., Spino C., et al. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with >or =400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 173 6 (1996) 1336-1346
34. Davey Jr. R.T., Murphy R.L., Graziano F.M., Boswell S.L., Pavia A.T., Cancio M., et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 284 2 (2000) 183-189
35. Lange C.G., Lederman M.M., Medvik K., Asaad R., Wild M., Kalayjian R., et al. Nadir CD4+T-cell count and numbers of CD28+CD4+T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 17 14 (2003) 2015-2023
36. Hardy G.A., Imami N., Nelson M.R., Sullivan A.K., Moss R., Aasa-Chapman M.M., et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vac 5 (2007) 6
37. Hess C., Altfeld M., Thomas S.Y., Addo M.M., Rosenberg E.S., Allen T.M., et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 363 9412 (2004) 863-866